It is currently unknown whether tumor-associated factors, including mutations in the antigen processing and presentation pathways, loss of antigen expression or insensitivity to T cell effector molecules are associated with resistance to CD38-targeting antibodies. The gene discussed is CD38; the disease is neoplasm.